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Summary.-The hypothesis that there is prostaglandin-mediated hypercalcaemia
associated with the Walker carcinosarcoma in the rat was tested by measuring PGE
production during the development of the hypercalcaemia, and determining the
effects of inhibition of prostaglandin synthesis on serum calcium concentration.
Parathyroid hormone (PTH) activity was estimated by the determination of the
serum concentration of immunoreactive PTH. There was a 3-fold increase in the
urinary excretion of 7oa-hydroxy-5, 1 -diketotetranor -prostane - 1,16-dioic acid
(PGE-M), a major urinary metabolite of the E prostaglandins from basal levels.
Treatment with indomethacin, a potent inhibitor of prostaglandin synthesis, did not
lower serum calcium concentrations with two different doses (1-6 mg/kg/day orally
and 5 mg/kg/day i.m.); effective inhibition of prostaglandin synthesis was demon-
strated by the suppression of PGE-M excretion rates below basal levels. Serum
concentrations of immunoreactive PTH were not significantly altered by either
tumour growth or indomethacin. Dexamethasone (0 5 mg/kg/day i.m.) attenuated
both the increased urinary excretion of PGE-M and the rise in serum calcium con-
centration, suggesting that one or several lipoxygenase products might be the actual
mediators of the hypercalcaemia. We conclude that the hypercalcaemia in the rat
with Walker carcinosarcoma is probably not mediated by E-prostaglandins and
probably not by any other product of the cyclo-oxygenase pathway. The increased
PGE turnover may be considered as a biochemical marker of tumour load, but not
as an indicator of a prostaglandin-mediated hypercalcaemia.
C,ERTAIN types of hypercalcaemia in
malignancy of both experimental animals
and man may be mediated by prosta-
glandins (Tashjian, 1978; Seyberth et al.,
1978; Seyberth, 1978). The humoral
mediator ofthe hypercalcaemia associated
with the Walker carcinosarcoma in the rat
has not been conclusively identified
(Mundy, 1978). This animal model is often
used to study the pathogenesis of hyper-
calcaemia in breast cancer; the Walker
carcinosarcoma was derived from a spon-
taneously developed tutmour of the rat
mammary gland (Minne et al., 1975). At
least two candidates have been proposed
as mediators of this type of hyper-
calcaemia: a parathyroid hormone (PTH)-
like compound (Minne et al., 1975, 1978)
and a prostaglandin, most likely PGE2
(Powles et al., 1973; Spiro & Mundy, 1979).
We have investigated the hypothesis
that hypercalcaemia in the Walker car-
cinosarcoma rat is prostaglandin-medi-
ated. First, we assessed in vivo PGE2 pro-
duction during tumour growth and the
development of hypercalcaemia, and
second, we blocked prostaglandin syn-
thesis at the level of prostaglandin cyclo-
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oxygenase, and we tried to inhibit the
release from phospholipids of arachidon-
ate, the major substrate for prostaglandin
synthesis. In some of these experiments
immunoreactive PTH was determined
during the pharmacological interventions.
Total PGE turnover in the rat was
assessed by determining the excretion of
a major urinary PGE-metabolite, 7a-
hydroxy - 5,11 - diketotetranorprostane - 1,
16-dioic acid (Green, 1971; Hamberg,
1972) and, as an index of renal PGE2
synthesis, the urinary output ofPGE2 was
also determined (Frolich et al., 1975).
Prostaglandin cyclooxygenase was in-
hibited by treatment with indomethacin
(Flower, 1974); and dexamethasone was
selected as an anti-inflammatory gluco-
corticoid which can prevent arachidonate
release from phospholipids in cell culture
and in isolated perfused organs (Tam et al.,
1977; Lands, 1979). Both kinds ofpharma-
cological intervention have been used to
demonstrate a prostaglandin-mediated
hypercalcaemia associated with the
HSDM1 fibrosarcoma in the mouse (Tash-
jian et al., 1977a) and with the VX2
carcinosarcoma in the rabbit (Seyberth et
al., 1977; Tashjian et al., 1977b).
MATERIALS AND METHODS
Experimental desi.qn.-We performed two
experiments in which 0-2 ml of a cell suspen-
sion (about 2 x 107 cells) of the Walker
ascites carcinosarcoma was injected s.c. on
the back of 220g female Sprague-Dawley
rats (Siiddeutsche Zuchtanstalt, Tuttlingen,
W. Germany). The rats were maintained on a
standard laboratory chow (Ssniff, Soest, W.
Germany) and tap water ad libitum. For the
determination of urinary excretion rates of
prostaglandins, rats were kept overnight for
14 h in metabolism cages; the total urine was
collected into ice-cold flasks. The samples
were then removed and stored at -70°C
before the determination of PGE-M, PGE2
and creatinine.
In thefirst experiment, urine was collected
the night before tumour transplantation and
on the 6th and 8th days of tumour growth.
Blood was also sampled on Days 6 and 8 for
serum calcium, and on the 8th day only for
PTH analysis; the animals were sacrificed.
The test animals (n=7) were treated orally
at 08.00 and 20.00 with 0-8 mg of indo-
methacin/kg body weight. The concurrent
controls (n=6) were handled in the same way
except that they received no drug.
In the second experiment, animals were
divided randomly into 3 groups (n=8):
controls, indomethacin treatment (5 mg/kg/
day, i.m.) and dexamethasone treatment
(0 5 mg/kg/day, i.m.). Drugs were given at
08.00 and 20.00 beginning on the 5th day
after tumour transplantation. These changes
in the experimental design were necessary to
prevent major side effects of indomethacin
(e.g. intestinal ulceration and renal failure)
and differences in tumour growth between
the controls and dexamethasone-treated rats.
At the end of this experiment indomethacin
and dexamethasone serum levels were deter-
mined in the middle of the dosage interval.
Tumour size was assessed by weight and by
volume (V) which was calculated from the
equation V=7rTW2L/6. Width (W) and length
(L) were measured with calipers. In addition,
tumour tissue was dissected immediately and
fixed in buffered 4% formaldehyde solution,
embedded in ParaplastR (Lancer, St Louis,
Mo, U.S.A.) and 4-5,tm sections were stained
with haematoxylin-eosin.
Prostaqlandin analysis.-The determina-
tion of urinary levels of PGE-M and PGE2
was by quantitative mass spectrometry. 3H-
labelled biosynthesized PGE-M (Seyberth et
al., 1976b) (s 12 x 104 ct/min sp. act. 150 Ci/
mmol) and 1 ,ug of3,3,4,4-tetradeutero-PGE2
together with 3H-labelled, synthetic PGE2
(~-15 x 104 ct/min; sp. act. 120-170 Ci/
mmol) were added to 5 ml ofrat urine and the
pH was adjusted to 3-2 with formic acid. The
ethyl acetate extract was concentrated and
chromatographed on a 2g open silica-gel
column (lem i.d.) using the solvent system
ethyl acetate: toluene (7: 3). PGE-M and
PGE2 were eluted in 100 ml. After methyla-
tion with freshly prepared diazomethane, the
material was subjected to high-performance
liquid chromatography (HPLC) using a 10lm
silica-gel column (Seyberth et al., 1976b).
Because no 2H-labelled PGE-M was present
in the sample up to this preparative step, the
radioactivity in the PGE-M peak of the
HPLC chromatogram was determined, to
assess the recovery of PGE-M. Subsequently
eluates of PGE-M and PGE2 were converted
to the methoxime and trimethylsilylether
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derivatives. After adding 1 Ig of d3-meth-
oxime derivative of the methylester of PGE-
M to the PGE-M sample, the isotope ratios
were determined with a gas chromatography-
mass spectrometry (GC-MS) system.
Miscellaneous procedures.-Serum PTH
concentration was determined by radio-
immunoassay according to the procedure of
Streibl et al. (1979). This method can detect
serum PTH values in normal rats and can
clearly discriminate between intact and para-
thyroidectomized rats (Minne et al., un-
published). Serum concentrations of indo-
methacin were determined by the HPLC
method of Skellern & Salole (1975). Serum
concentrations of dexamethasone were also
determined by HPLC: serum (500 ,ul) was
diluted 1:1 with water, poured on to 2 g of
ExtrelutR (E. Merck, Darmstadt, W. Ger-
many) and eluted with ethyl acetate (25 ml).
The evaporated extract was reconstituted in
eluent and chromatographed on a PorasilR
column (Waters Associates, Milford, Mass.,
U.S.A.) with the eluent dichloromethane:
methanol:glacial acetic acid (97:3:0-1); the
detector was set at 254 nm. Prednisolone was
used as the internal standard. Serum calcium
concentrations were determined with a
Corning 940 Analyser and the determinations
ofcreatinine were performed with a Beckman
Creatinine-Analyser II.
Materials and equipment.-All solvents
were glass-distilled reagents from Prochem
Company (Wesel, W. Germany). Unlabelled
and tetradeuterated PGE2 was generously
provided by Dr U. Axen, The Upjohn Com-
pany (Kalamazoo, Mich., U.S.A.). Tritiated
PGE2 and 15-keto-13,14-dihydro PGE2 (sp.
act. 150 Ci/mmol) were obtained from
Amersham Buchler (Braunschweig, W. Ger-
many). Chemically synthesized PGE-M was
donated by Drs J. R. Boot and N. J. A.
Gutheridge, The Lilly Research Centre Ltd
(Windlesham, England). d3-Methoxyamine
HC1 was purchased from Serva (Heidelberg,
W. Germany) and N,O-bis (trimethylsilyl)
trifluoroacetamide from Fluka AG (Buchs,
Switzerland) respectively.
Diazomethane was prepared as described
previously (Sweetman et al., 1973). Indo-
methacin and dexamethasone were gifts from
Sharp and Dohme (Munich, W. Germany).
The aqueous indomethacin sodium salt solu-
tion was prepared by neutralization of indo-
methacin with sodium carbonate. Pred-
nisolone was provided by E. Merck (Darm-
stadt, W. Germany).
HPLC of prostaglandins was performed
with two Waters Associates (Milford, Mass.,
U.S.A.) pumps (Model 6000 A) coupled to a
solvent-flow programmer (Model 660). The
silica-gel column was a prepacked 10,um
Porasil column (Waters Associates). For
mass-spectrometric analysis a Hewlett-
Packard HP 5992 A microprocessor-con-
trolled GC-MS system (Hewlett-Packard
Company, Palo Alto, Calif., U.S.A.) equipped
with a glass capillary column (Erlenmaier et
al., 1979) and working in the selected ion-
monitoring mode was used.
Statistical methods.-Where appropriate,
the results were subjected to an analysis of
variance followed by analysis of co-variance
and the Scheff6 test. Otherwise the rank-sign
sum test was applied.
RESULTS
Five to 6 days after tumour transplanta-
tion, the Walker carcinosarcoma started
to grow rapidly from an almost non-
palpable tumour to a tumour of 7.4 + 4-4 g
(mean + s.d.) in the untreated rats and
6-4 + 1 7 g in the indomethacin-treated
rats within 2 days. During that time
hypercalcaemia was present in most rats
and the urinary excretion of PGE-M rose
about 3-fold (Fig. IA). The animals with
the highest PGE-M excretion rates were
usually the ones with the highest serum
calcium concentrations. However, the
hypercalcaemia in the indomethacin-
treated rats was in the same range as in
the control group, despite a significant
decrease of PGE-M excretion below the
basal level (Fig. IB). Serum concentrations
of immunoreactive PTH were 3*7 + 1-2 ,u
S.U.I./100 ,A in the untreated rats and
3'4+1.0 ,u S.U.L./100 pl in the indo-
methacin-treated animals, which were not
significantly different from those of un-
treated control rats (3.1 + 0-6 ,ul S.U.I./
100 t1).
Pharmacological intervention in the
second experiment was not started until
the 5th day after s.c. injection of the
ascites cells ofthe Walker carcinosarcoma.
The drug concentrations in the middle of
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the dosage interval were 19X2 + 2-6 jug
indomethacin/ml and 0d143 + 0077 4tg
dexamethasone/ml. The effects ofthe drug
treatments on the 8th day after tumour
transplantation on urinary excretion of
PGE-M and PGE2, serum calcium concen-
tration and tumour weight are shown in
Fig. 2. The Walker carcinosarcoma-bear-
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FIG. 1. Time course of the rise in urinary
PGE-M excretion and serum calcium con-
centrations in Walker carcinosarcoma-bear-
ing rats: (A) no pharmacological interven-
tion; (B) indomethacin treatment (0-8 mg/
kg, orally twice a day) starting one day
before tumour transplantation. The shaded
area represents the normal range of serum
calcium concentration. Values from each
rat are identified by a separate symbol. All
the compared means for PGE-M were sig-
nificantly different at a level of P < 001.
CR =urinary creatinine.
ing rats excreted 2-3 times more PGE-M
than normal rats. Indomethacin markedly
suppressed the PGE-M excretion below
the normal range, while dexamethasone
reduced to only a small extent the in-
creased urinary PGE-M excretion rate.
Urinary PGE2 excretion, a parameter of
renal PGE2 synthesis, was not significantly
altered in the Walker tumour-bearing
rats, indicating that mainly systemic
PGE-production contributes to the
elevated PGE-M excretion in these rats.
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FIG. 2. Effects of indomethacin or dexa-
methasone on urinary PGE-M and PGE2
excretion, on serum calcium concentration
and on tumour weight in Walker tumour-
bearing rats. Treatments (5 mg of indo-
methacin/kg/day or 0 5 mg of dexametha-
sone/kg/day i.m., respectively) were started
5 days after tumour transplantation and
continued to the 8th day, when the animals
were killed. Bars give the median for each
group. Each rat is represented by a different
symbol. The shaded area represents the
mean + 2 s.d. of 6 normal concurrent
control rats. Cr =urinary creatinine.
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DISCUSSION
Incireased systemic PGE prod
associated with grow th of t
ely abolished carcinosarcoma in both experiments. The
-thasone did tissue or organ which contributes most to
PGE2 excre- this increased PGE turnover remains to
tion of sys- be identified; the tumour, an activated
iction, indo- immune system or the bone tissue are
rum calcium possibilities.
rum calcium Two different doses of indomethacin
the indo- failed to affect the hypercalcaemia in the
ited with a tumour-bearing rats, despite marked in-
,th. In all 3 hibition of PGE production. By the
rne were not criteria of a prostaglandin-mediated pro-
iere was no cess (Needleman, 1.978) one has to exclude
Air histology, E-prostaglandins and probably any other
tor, cells or product ofthe cyclo-oxygenase pathway as
the mediator of this hypercalcaemia.
nouir weight, These findings do not corroborate those of
n. Irrespec- Powles et al. (1973) who observed a de-
close corre- crease in the high serum calcium concen-
parameters. trations in rats bearing the Walker tumour
nship when when they treatred these aninmals with a
by tumour combination of two cyclo-oxygenase in-
0 725). The hibitors, aspirin and indomethacin, be-
itrations of ginning 3 days before tumour-cell injec-
ls can also tion. Although prostaglandin production
the calcium had not been monitored in these studies,
treated rats one may assume some inhibition ofprosta-
n line. glandin synthesis by this kind of treat-
ment. However, there were some possibly
rlelevant, differences in the experimental
design: first the method of injecting the
tumouir cells (intra-arterially vs s.c.) and
second, possible differences in the genetic
A make-up of the tumour lines. Recently
Spiro & Mutndy (1979) reported in pre-
liminary form that there is a close corre-
lation between production of bone re-
sorbing activity by different Walkei
carcinosarcoma cell clones and the release
y=0.454x13x745 of immunoreactive E-prostaglandins into
r=0,784 the medium. Therefore, bone metastases
of some tumour lines may contribute to
'-7s localized osteolysis in the Waalker-bearing
rats. However, as shown with our strain,
ir we'ight factors unrelated to prostaglandins have I1 in t2: to be considered as humoral mediators of
atedl. C);ythe hypercalcaemia, suich as a PTH-like
compound or an osteoclast-activating fac-
tor (OAF).
Dexamathasonie was chosen as a
Iuctioin was pharmacological intervention to differ-
-he W"alker entiate between gltucocorticoid-resistant,
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PTH-mediated hypercalcaemia (Dent,
1962; Raisz et al., 1972) and a highly
glucocorticoid - sensitive, OAF - induced
hypercalcaemia (Mundy, 1978; Mundy et
al., 1978) in addition to the intervention at
a different level ofprostaglandin synthesis.
Although we have not measured OAF, it
appears unlikely that this factor is the
hypercalcaemic mediator, as intact prosta-
glandin synthesis is required for OAF pro-
duction (Yoneda & Mundy, 1979). The
small lowering effect of dexamethasone on
serum calcium does not argue against a
PTH-mediated hypercalcaemia, because
the dexamethasone serum concentrations
in the rats are similar to those which have
a direct inhibitory effect on bone-cell
function in vitro (Raisz et al., 1972; Chen
& Feldman, 1979). In addition, serum
concentrations of immunoreactive PTH
in the upper normal range in the hyper-
calcaemic rats support the PTH hypo-
thesis, particularly when the antiserum in
the radioimmunoassay may cross-react
only in part with ectopically secreted
PTH. Serum concentrations of immuno-
reactive PTH were inappropriately high
for a hypercalcaemic state, and previous
experiments have shown that indometh-
acin does not influence PTH-induced
hypercalcaemia (Seyberth et al., 1976a).
However, for the final proofof a PTH-like
compound as the mediator of the hyper-
calcaemia in the Walker tumour-bearing
rat, studies with inhibitors of PTH pro-
duction or with PTH antagonists will have
to be performed. An alternative hypo-
thesis to PTH-mediated hypercalcaemia
is that the hypercalcaemia-inducing agent
is a product synthesized via the lipoxy-
genase pathway of arachidonate metab-
olism; this pathway is not inhibited by
indomethacin (Hamberg & Samuelsson,
1974). Only an earlier intervention in the
metabolism of arachidonate, such as the
inhibition of its release from phospho-
lipids, would prevent the production of
metabolites of the cyclo-oxygenase and
lipoxygenase pathways. The small but
concomitant decrease of calcium concen-
tration and PGE-M excretion in the rats
treated with dexamethasone suggests that
a lipoxygenase product is the actual
mediator of the hypercalcaemia, whilst
the stimulated PGE turnover is an asso-
ciated biochemical event, without any
causal relationship to the pathogenesis of
the hypercalcaemia. Unfortunately, as
demonstrated in our experiments, dexa-
methasone does not appear to be an ideal
pharmacological tool for manipulating
prostaglandin production in vivo, though
the serum concentrations of dexameth-
asone were higher than those which inhibit
prostaglandin release in vitro (Tam et al.,
1977). Therefore, there is apparently still
sufficient non-esterified arachidonic acid
available, to be metabolized by lipoxy-
genase to a variety of hydroxy poly-
unsaturated fatty acids (Borgeat &
Samuelsson, 1979; Murphy et al., 1979).
More effective and specific inhibitors of
lipoxygenase, and more knowledge about
the effects of these eicosonides on calcium
and bone metabolism, are needed to ex-
clude an eicosonide-mediated hyper-
calcaemia.
In conclusion, there is an increased
PGE production in the Walker careino-
sarcoma-bearing rat, which is unrelated
to the paraneoplastic syndrome of hyper-
calcaemia. The humoral mediator remains
to be identified. The only parameter
closely correlated with the serum calcium
concentration is tumour size.
The urinary excretion of PGE-M may
be considered as a biochemical marker of
tumour load, but not as an indicator of a
prostaglandin-mediated hypercalcaemia in
the WTalker carcinosarcoma-bearing rat.
This observation may be applicable also
to certain human tumours, as recently
shown in a breast cancer patient with
increased production of immunoreactive
PGE2, in whom hypercalcaemia was un-
affected by indomethacin treatnment (Caro
etal., 1979).
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